Familial combined hyperlipidemia and familial hypertriglyceridemia were both associated with an identical increased risk of coronary artery disease (OR 2.0; P=0.003 and P=0.002, respectively).
Case-Control (n=627)
Does familial combined hyperlipidemia or familial hypertriglyceridemia increase the risk of premature coronary artery disease compared to controls?
FCHL and FHTG carry a similar increased risk for premature CAD, which is largely driven by the high prevalence of concurrent metabolic syndrome, challenging the conventional wisdom that FHTG is benign.
Effect estimate: OR 2.0
p-value: p=0.003 and 0.002
BACKGROUND: Conventional wisdom suggests that a diagnosis of familial combined hyperlipidemia (FCHL) carries a substantially greater risk of premature coronary artery disease (CAD) than a diagnosis of familial hypertriglyceridemia (FHTG). However, no population-based studies have critically addressed this issue. METHODS AND RESULTS: FCHL and FHTG were diagnosed in 10.2% and 12.3% of 334 random control families and in 16.7% and 20.5% of 293 families with at least one case of premature CAD. The diagnosis of either FCHL or FHTG in an individual was associated with an odds ratio for CAD of 2.0 (P=0.003 and 0.002, respectively). However, odds ratios for premature CAD associated with both lipid disorders decreased substantially and identically with further adjustment for hypertension, diabetes, and especially HDL cholesterol, triglycerides, or apolipoprotein B. Similar results were found for differences in carotid intima-medial thickness and ankle-brachial index. Metabolic syndrome was identified in 65% of FCHL and 71% of FHTG patients compared with 19% in controls without FCHL or FHTG and was associated with an odds ratio of 3.3 (P<0.0001). The increased prevalence of the metabolic syndrome alone could account for the elevated CAD risk associated with both FCHL and FHTG. CONCLUSIONS: FCHL and FHTG appear more alike than dissimilar. Further, the risk of CAD in FCHL and FHTG was strongly related to features of the metabolic syndrome. These findings suggest that the hypertriglyceridemia in FHTG is not benign and may warrant a change in epidemiological, genetic, and clinical approaches to these lipid disorders.
Hopkins et al. (Tue,) conducted a case-control in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia (n=627). Familial combined hyperlipidemia (FCHL) and familial hypertriglyceridemia (FHTG) vs. Controls without FCHL or FHTG was evaluated on Coronary artery disease (CAD) (OR 2.0, p=0.003 and 0.002). Familial combined hyperlipidemia and familial hypertriglyceridemia were both associated with an identical increased risk of coronary artery disease (OR 2.0; P=0.003 and P=0.002, respectively).